Bernd Meibohm

The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.

Real-time PCR-based genotyping assay for CXCR2 polymorphisms.

Pharmacokinetic aspects of biotechnology products.

SYBR Green-based real-time PCR allelic discrimination assay for beta2-adrenergic receptor polymorphisms.

The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.

Population pharmacokinetic studies in pediatrics: issues in design and analysis.

G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression.

LC/MS/MS in drug development: targeting the brain.

Discovery of novel isoxazolines as anti-tuberculosis agents.

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs.

Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents.

A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.

A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens.

Concepts and challenges in quantitative pharmacology and model-based drug development.

A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.

Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score.

Genetic ancestry in lung-function predictions.

Population pharmacokinetics of therapeutic monoclonal antibodies.

Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.

Pharmacokinetics of a combination of Δ9-tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock.

In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.

Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?

Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function.

Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.

Population pharmacokinetic/pharmacodynamic analyses as the basis for dosing of therapeutic monoclonal antibodies.

Characterizing the impact of renal impairment on the clinical pharmacology of biologics.

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.

Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.

Genetic ancestry-smoking interactions and lung function in African Americans: a cohort study.

The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease.

The current role of model-based drug development.

Genome Wide Association Studies Identify CHRNA5/3 and HTR4 in the Development of Airflow Obstruction.

Developing a gene expression model for predicting ventilator-associated pneumonia in trauma patients: a pilot study.

Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.

Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: improved applicability to pharmacokinetic study.

Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function.

Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants.

Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.

Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.

Pharmacokinetic profile of spectinomycin in rats.

Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux.

Novel endogenous glycan therapy for retinal diseases: safety, in vitro stability, ocular pharmacokinetic modeling, and biodistribution.

Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis.

Large-scale genome-wide association studies and meta-analyses of longitudinal change in adult lung function.

Protein engineering for improved pharmacologic characteristics of established monoclonal antibody-based therapeutics.

Effects of alcohol on human carboxylesterase drug metabolism.

Ethanol lock therapy: a pilot infusion study in infants.

Clinical pharmacology of bispecific antibody constructs.

Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections.

Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group.

Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.

Pattern Recognition in Pharmacokinetic Data Analysis.

In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics.

Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.

Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis.

Phase II Metabolic Pathways of Spectinamide Antitubercular Agents: A Comparative Study of the Reactivity of 4-Substituted Pyridines to Glutathione Conjugation.

Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver.

Drug Development of Therapeutic Monoclonal Antibodies.

Translational PK/PD of anti-infective therapeutics.

Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure.

Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions.

Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.

A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.

Regulatory and Ethical Issues in Pediatric Clinical Research: Recommendations From a Panel Discussion.

Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics.

Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.

Pharmacokinetics of Monoclonal Antibodies.

Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects.

Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.

Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular .

Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells.

Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology.

The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360.

The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360.

Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis.

Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice.

Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Common Problem Drugs and How to Prescribe Them.

Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.

Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.

Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies.

Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.

Immunogenicity in Clinical Practice and Drug Development: When is it Significant?

Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis.

Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients.

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients.

Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS.

Discovery of -(3,4-Dimethylphenyl)-4-(4-isobutyrylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-]quinoline-8-sulfonamide as a Potent Dual MDM2/XIAP Inhibitor.

Use of Real-World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age.

Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction.

Pediatric Dose Selection for Therapeutic Proteins.

Time to 'Mind the Gap' in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2.

X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.

Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis.

Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and Study.

Knowledge Gaps in the Pharmacokinetics of Therapeutic Proteins in Pediatric Patients.

Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer.

Alcohol inhibits the metabolism of dimethyl fumarate to the active metabolite responsible for decreasing relapse frequency in the treatment of multiple sclerosis.

SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.

Spray dried tigecycline dry powder aerosols for the treatment of Nontuberculous mycobacterial pulmonary infections.

Barriers to global pharmacometrics: educational challenges and opportunities across the globe.

TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival.

TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival.

Efficacy of a brain-penetrant antiviral in lethal Venezuelan and eastern equine encephalitis mouse models.

Novel, Brain-Permeable, Cross-Species Benzothiazole Inhibitors of Microsomal Prostaglandin E Synthase-1 (mPGES-1) Dampen Neuroinflammation and .

Design, Synthesis, and Biological Evaluation of Pyrimidine Dihydroquinoxalinone Derivatives as Tubulin Colchicine Site-Binding Agents That Displayed Potent Anticancer Activity Both In Vitro and In Vivo.

Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes.

Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates.

Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule.

Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics.

The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders.